VERTEX PHARMACEUTICALS INC / MA Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2026-06-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-12-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-09-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2025 was $379.00M.
- VERTEX PHARMACEUTICALS INC / MA impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2024 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2023 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2020 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month as first filed | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 | $0.00 derived: sum of 2 quarters · filed 2026-05-05 | $0.00 derived: sum of 3 quarters · filed 2026-05-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $0.00 derived: sum of 2 quarters · filed 2026-02-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $379.00M 10-K · filed 2026-02-13 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2026-08-04 | $379.00M 10-Q · filed 2025-11-04 | $379.00M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-04 | $379.00M 10-Q · filed 2026-08-04 | $379.00M derived: sum of 3 quarters · filed 2026-08-04 | $379.00M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $379.00M 10-Q · filed 2026-08-04 | $379.00M derived: sum of 2 quarters · filed 2026-08-04 | $379.00M derived: sum of 3 quarters · filed 2026-08-04 | $379.00M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $0.00 derived: sum of 2 quarters · filed 2026-02-13 | $0.00 derived: sum of 3 quarters · filed 2026-02-13 | $0.00 10-K · filed 2026-02-13 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-06 | |||||
| 2023-12-31 | $0.00 10-K · filed 2026-02-13 | |||||
| 2020-12-31 | $0.00 10-K · filed 2021-02-11 | |||||
| 2019-12-31 | $0.00 10-K · filed 2021-02-11 | |||||
| 2018-12-31 | $29.00M 10-K · filed 2020-02-13 | $29.00M derived: sum of 2 quarters · filed 2020-02-13 | $29.00M derived: sum of 3 quarters · filed 2020-02-13 | $29.00M 10-K · filed 2021-02-11 | ||
| 2018-09-30 | $0.00 10-K · filed 2020-02-13 | $0.00 derived: sum of 2 quarters · filed 2020-02-13 | $0.00 10-Q · filed 2018-10-25 | $0.00 derived: sum of 4 quarters · filed 2020-02-13 | ||
| 2018-06-30 | $0.00 10-K · filed 2020-02-13 | $0.00 derived: sum of 2 quarters · filed 2020-02-13 | $0.00 derived: sum of 3 quarters · filed 2020-02-13 | $255.34M derived: sum of 4 quarters · filed 2020-02-13 | ||
| 2018-03-31 | $0.00 10-K · filed 2020-02-13 | $0.00 derived: sum of 2 quarters · filed 2020-02-13 | $255.34M derived: sum of 3 quarters · filed 2020-02-13 | $255.34M derived: sum of 4 quarters · filed 2020-02-13 | ||
| 2017-12-31 | $0.00 10-K · filed 2019-02-13 | $255.34M derived: sum of 2 quarters · filed 2019-02-13 | $255.34M derived: sum of 3 quarters · filed 2019-02-13 | $255.34M 10-K · filed 2020-02-13 | ||
| 2017-09-30 | $255.34M 10-K · filed 2019-02-13 | $255.34M derived: sum of 2 quarters · filed 2019-02-13 | $255.34M 10-Q · filed 2018-10-25 | $255.34M derived: sum of 4 quarters · filed 2019-02-13 | ||
| 2017-06-30 | $0.00 10-K · filed 2019-02-13 | $0.00 derived: sum of 2 quarters · filed 2019-02-13 | $0.00 derived: sum of 3 quarters · filed 2019-02-13 | $0.00 derived: sum of 4 quarters · filed 2019-02-13 | ||
| 2017-03-31 | $0.00 10-K · filed 2019-02-13 | $0.00 derived: sum of 2 quarters · filed 2019-02-13 | $0.00 derived: sum of 3 quarters · filed 2019-02-13 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $0.00 derived: sum of 2 quarters · filed 2019-02-13 | $0.00 10-K · filed 2019-02-13 | |||
| 2016-09-30 | $0.00 10-Q · filed 2017-10-30 | $0.00 10-Q · filed 2017-10-30 | ||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-15 | |||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $0.00 derived: sum of 2 quarters · filed 2016-02-16 | $0.00 derived: sum of 3 quarters · filed 2016-02-16 | $0.00 10-K · filed 2016-02-16 | ||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-06 | $0.00 derived: sum of 2 quarters · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 | $0.00 derived: sum of 4 quarters · filed 2015-02-13 | ||
| 2014-06-30 | $0.00 10-Q · filed 2014-07-31 | $0.00 10-Q · filed 2014-07-31 | $0.00 derived: sum of 3 quarters · filed 2015-02-13 | $0.00 derived: sum of 4 quarters · filed 2015-02-13 | ||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-05 | $0.00 derived: sum of 2 quarters · filed 2015-02-13 | $0.00 derived: sum of 3 quarters · filed 2015-02-13 | $0.00 derived: sum of 4 quarters · filed 2015-02-13 | ||
| 2013-12-31 | $0.00 10-K · filed 2015-02-13 | $250.60M 10-K · filed 2014-02-11 | $0.00 derived: sum of 2 quarters · filed 2015-02-13 | $0.00 derived: sum of 3 quarters · filed 2015-02-13 | $412.90M 10-K · filed 2016-02-16 | $663.50M 10-K · filed 2014-02-11 |
| 2013-09-30 | $0.00 10-K · filed 2015-02-13 | $0.00 derived: sum of 2 quarters · filed 2015-02-13 | $412.90M 10-Q · filed 2014-11-06 | $412.90M derived: sum of 4 quarters · filed 2015-02-13 | ||
| 2013-06-30 | $0.00 10-K · filed 2015-02-13 | $412.90M 10-Q · filed 2014-07-31 | $412.90M derived: sum of 3 quarters · filed 2015-02-13 | $412.90M derived: sum of 4 quarters · filed 2015-02-13 | ||
| 2013-03-31 | $412.90M 10-K · filed 2015-02-13 | $412.90M derived: sum of 2 quarters · filed 2015-02-13 | $412.90M derived: sum of 3 quarters · filed 2015-02-13 | $412.90M derived: sum of 4 quarters · filed 2015-02-13 | ||
| 2012-12-31 | $0.00 10-K · filed 2014-02-11 | $0.00 derived: sum of 2 quarters · filed 2014-02-11 | $0.00 derived: sum of 3 quarters · filed 2014-02-11 | $0.00 10-K · filed 2015-02-13 | ||
| 2012-09-30 | $0.00 10-K · filed 2014-02-11 | $0.00 derived: sum of 2 quarters · filed 2014-02-11 | $0.00 10-Q · filed 2013-11-07 | $0.00 derived: sum of 4 quarters · filed 2014-02-11 | ||
| 2012-06-30 | $0.00 10-K · filed 2014-02-11 | $0.00 10-Q · filed 2013-08-02 | $0.00 derived: sum of 3 quarters · filed 2014-02-11 | $105.80M derived: sum of 4 quarters · filed 2014-02-11 | ||
| 2012-03-31 | $0.00 10-K · filed 2014-02-11 | $0.00 derived: sum of 2 quarters · filed 2014-02-11 | $105.80M derived: sum of 3 quarters · filed 2014-02-11 | $105.80M derived: sum of 4 quarters · filed 2014-02-11 | ||
| 2011-12-31 | $0.00 10-K · filed 2013-03-01 | $105.80M derived: sum of 2 quarters · filed 2013-03-01 | $105.80M derived: sum of 3 quarters · filed 2013-03-01 | $105.80M 10-K · filed 2014-02-11 | ||
| 2011-09-30 | $105.80M 10-K · filed 2013-03-01 | $105.80M derived: sum of 2 quarters · filed 2013-03-01 | $105.80M 10-Q · filed 2012-11-06 | |||
| 2011-06-30 | $0.00 10-K · filed 2013-03-01 | $0.00 derived: sum of 2 quarters · filed 2013-03-01 | ||||
| 2011-03-31 | $0.00 10-K · filed 2013-03-01 | |||||
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 | |||||
| 2009-12-31 | $7.20M 10-K · filed 2011-02-17 | $7.20M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |